JPMorgan Initiates Cidara Stock Coverage with $200 Price Target on Flu Drug Potential

JPMorgan sets $200 price target for Cidara Therapeutics, citing "game-changing" flu treatment CD388 with projected $4B peak U.S. sales and 75% success probability